- Report
- October 2026
- 254 Pages
Global
From €5388EUR$5,850USD£4,554GBP
- Report
- October 2026
- 215 Pages
Global
From €5388EUR$5,850USD£4,554GBP
- Report
- October 2026
- 220 Pages
Global
From €5388EUR$5,850USD£4,554GBP
- Report
- October 2026
- 239 Pages
Global
From €5388EUR$5,850USD£4,554GBP
- Report
- October 2026
- 238 Pages
Global
From €5388EUR$5,850USD£4,554GBP
- Report
- October 2026
- 657 Pages
Global
From €5388EUR$5,850USD£4,554GBP
- Report
- October 2026
- 427 Pages
Global
From €5388EUR$5,850USD£4,554GBP
- Report
- October 2026
- 293 Pages
Global
From €5388EUR$5,850USD£4,554GBP
- Report
- October 2026
- 279 Pages
Global
From €5388EUR$5,850USD£4,554GBP
- Report
- October 2026
- 273 Pages
Global
From €5388EUR$5,850USD£4,554GBP
- Report
- October 2026
- 594 Pages
Global
From €5388EUR$5,850USD£4,554GBP
- Report
- October 2026
- 279 Pages
Global
From €5388EUR$5,850USD£4,554GBP
- Report
- October 2026
- 181 Pages
Global
From €5388EUR$5,850USD£4,554GBP
- Report
- October 2026
- 381 Pages
Global
From €5388EUR$5,850USD£4,554GBP
- Report
- October 2026
- 371 Pages
Global
From €5388EUR$5,850USD£4,554GBP
- Report
- October 2026
- 279 Pages
Global
From €5388EUR$5,850USD£4,554GBP
- Report
- October 2026
- 459 Pages
Global
From €5388EUR$5,850USD£4,554GBP
- Report
- October 2026
- 282 Pages
Global
From €5388EUR$5,850USD£4,554GBP
- Report
- October 2026
- 291 Pages
Global
From €5388EUR$5,850USD£4,554GBP
- Report
- July 2026
- 174 Pages
Global
From €7359EUR$7,990USD£6,219GBP

The Targeted Therapies market within the context of Genomics is focused on the development of treatments that target specific genetic mutations or pathways. These therapies are designed to be more effective and have fewer side effects than traditional treatments. Genomics has enabled the development of personalized treatments that are tailored to the individual patient's genetic makeup. This has allowed for the development of drugs that target specific mutations or pathways, leading to more effective treatments.
The Targeted Therapies market is a rapidly growing field, with many companies investing in research and development. Companies such as Gilead Sciences, Novartis, and AstraZeneca are leading the way in the development of targeted therapies. Other companies such as Merck, Pfizer, and Roche are also investing in the development of targeted therapies. Show Less Read more